Family Medicine Doctors in Carrollton, AL Accepting Medicare
1 Family Medicine doctors found. Showing 1 - 1
 Brittney Anderson, Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 289 William E Hill Dr, Carrollton, AL 35447 Phone: 205-367-2455 Fax: 205-367-2496 |
News Archive
Belfer Institute, sanofi-aventis collaborate to discover anticancer drugs
Dana-Farber Cancer Institute's Belfer Institute of Applied Cancer Science (Belfer Institute) and sanofi-aventis announced today that they have entered into a collaboration and license option agreement to identify and validate novel oncology targets for further discovery and development by sanofi-aventis of novel therapeutics agents directed to such targets and related biomarkers.
Pretreatment with FDA-approved drug allows successful pregnancies in radiation-exposed rhesus monkeys
A strategy developed by Massachusetts General Hospital (MGH) researchers to shield the ovaries of female mammals from the damaging effects of radiation and chemotherapy has passed an important milestone. A collaborative study with investigators from Oregon Health and Sciences University (OHSU), published online in the journal Fertility and Sterility, reports that brief preexposure of the ovaries to an FDA-approved agent called FTY720 preserved the fertility of female rhesus monkeys exposed to potentially lethal doses of radiation.
Scientists now closer to produce drugs to fix disease-causing mutations, spare healthy genes
Inherited diseases such as cystic fibrosis can be caused by genetic "nonsense mutations" that disrupt the way human cells make proteins. David Bedwell, Ph.D., a professor in the University of Alabama at Birmingham Department of Microbiology, says scientists are now closer to producing drugs that will fix this disruption and drastically improve treatment of genetic disease.
ArQule, Daiichi Sankyo announce decision to advance ARQ 197 into Phase 3 clinical trial for NSCLC
ArQule, Inc. and Daiichi Sankyo Co., Ltd. today announced that they will move forward with a Phase 3 clinical trial of ARQ 197, a small molecule inhibitor of the c-Met receptor tyrosine kinase, in patients with non-small cell lung cancer (NSCLC). In connection with this decision, the sponsor company, Daiichi Sankyo, will file a Special Protocol Assessment (SPA) with the U.S. Food and Drug Administration (FDA) for a trial comparing ARQ 197 plus erlotinib against erlotinib plus placebo.
› Verified 3 days ago